Vertex Pharma (VRTX) Tops Q2 EPS by 11c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Vertex Reports Second Quarter 2022 Financial Results
August 4, 2022 4:01 PM EDTProduct revenues of $2.20 billion, a 22% increase compared to Q2 2021
Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion
Recent exa-cel and VX-880 clinical data presentations demonstrate transformative potential for patients with sickle cell disease, beta thalassemia and type 1 diabetes
Multiple clinical programs entering or progressing through late-stage clinical development
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022 and updated its full year 2022 financial guidance.
With... More
